ProPhase Labs Provides Update on Linebacker-1 Cancer Co-Therapy Program and Outlines Development Strategy

Stock Information for ProPhase Labs Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ProPhase Labs Inc.

ProPhase Labs Unveils Project ZenQ-AI
ProPhase Labs Seeks to Transform Esophageal Cancer Detection and Management with Launch of its BE-Smart Test in H2 2024
ProPhase Labs Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ProPhase Labs Announces Financial Results for the Year Ended December 31, 2023 and Significant Progress in Its Strategic Initiatives
PROPHASE LABS TO PRESENT 2023 YEAR END FINANCIAL RESULTS ON MARCH 15, 2024
ProPhase Labs Announces Significant Progress in BE-Smart Esophageal Cancer Test Development USPTO grants additional broad patents for BE-SMART
ProPhase Labs Announces Preliminary Positive Results for Dietary Supplement Equivir
ProPhase Labs Ushers in New Genomics Era with Jason Karkus at the Helm of Nebula Genomics

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.